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Abstract
Background: Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality.
Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, which
has emerged as a new epigenetic biomarker for early detection of CRC. Previously, we reported that we identified
that CpG sites of SDC2 were aberrantly methylated in tumor tissues of most CRC patients through comprehensive
methylation analysis and demonstrated a high potential of quantification of SDC2 methylation in blood for early
detection of colorectal cancer. In this study, we aim to investigate the feasibility of quantifying SDC2 methylation in
stool DNA for the early detection of CRC. The objective of this study was to confirm a high frequency of SDC2
methylation in tumor tissues at various stages of CRC and investigate the feasibility of a quantitative test for SDC2
methylation in fecal DNA by highly sensitive and accurate real-time PCR for early detection of CRC.
Methods: Bisulfite-pyrosequencing assay was performed to measure the SDC2 methylation status in tissue samples.
For methylation analysis in stool DNA, a highly sensitive and accurate method was applied which implements
consecutive two rounds of PCR consisting of unidirectional linear target enrichment (LTE) of SDC2 and quantitative
methylation-specific real time PCR (qMSP) for SDC2, named as meSDC2 LTE-qMSP assay. Its limit of detection was 0.
1% methylation (corresponding to ~ 6 copies in total ~ 6200 genome copies).
Results: Positive SDC2 methylation was observed in 100% of primary tumors, 90.6% of adenomatous polyps, 94.1%
of hyperplastic polyps, and 0% of normal tissues. SDC2 methylation level also significantly (P < 0.01) increased
according to the severity of lesions. In stool DNA test for SDC2 methylation by LTE-qMSP comparing CRC patients
with various stages (I to IV) (n = 50) and precancerous lesions (n = 21) with healthy subjects (n = 22), the overall
sensitivity was 90.0% for detecting CRC and 33.3% for detecting small polyps, with a specificity of 90.9%.
Conclusions: Taken together, our result indicates that stool DNA-based SDC2 methylation test by LTE-qMSP is a
potential noninvasive diagnostic tool for early detection of CRC.
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Background
Colorectal cancer (CRC) is the second most common
cause of malignant deaths in industrialized countries,
and it is known to be major cause of cancer morbidity
and mortality [1, 2]. The 5-year survival rate for CRC
can be as high as 90%, if the cancer is detected at an
early stage, but it is estimated to be less than 10% if a
metastasis occurs [3]. Several CRC screening tools have
been developed to facilitate the early detection of CRC,
including colonoscopy and fecal occult blood testing
(FOBT) [4]. For the last 10 years, colonoscopy has been
preferred as a screening tool to detect CRC early [5].
However, the acceptance of screening colonoscopy
remains very low within the general public, for several
reasons including the need for extensive bowel prepar-
ation [4]. Meanwhile, noninvasive stool tests such as
immunochemical FOBT have been available so far as an
attractive alternative to screen people for colonoscopy
referral. However, this has limited use as a screening test
to detect of earlier stages of CRC because of its low
sensitivity in detecting stage I of CRC and advanced
adenoma, at 53 and 27%, respectively [6]. Thus,
significant efforts have been made to develop noninvasive
molecular tests using accurate molecular biomarkers to
detect CRC and colorectal adenomas at an early stage [7].
The aberrant methylation of genes is an epigenetic
change that induces gene silencing of tumor suppressor
genes, and it has been recognized as one of the most com-
mon molecular alterations in CRC and in other human
cancers [8–10]. Methylated DNA is known to be chem-
ically and biologically stable, it is less subjected to transi-
ent alterations, and it is readily detectable in many types
of body fluids including blood and stool. Therefore, aber-
rantly methylated specific DNA sites in solid tumors are
well suited as noninvasive molecular diagnostics for the
early cancer detection [11–13].
Several stool-based DNA methylation markers such as
TFPI2, VIM, SFRP2, NDRG4, BMP3, and SDC2 have
been previously described as potential markers for early
CRC detection [14–18]. Overall, these reports presented
sensitivities of 46 to 89% and specificities of 76.8 to 93%.
Notably Imperiale et al. [19] recently reported a new
stool DNA test to measure two methylation biomarkers
and seven site mutations of KRAS in addition to a
hemoglobin test in the stool sample. This combinatorial
test showed an overall sensitivity of 92% with a specifi-
city of 87% for CRC detection, and it was approved by
the US FDA in 2014.
We previously determined that normally unmethylated
CpG sites of SDC2 are predominantly methylated in
tumor tissues of CRC and subsequently demonstrated
that the aberrant methylation of SDC2 is frequently
detected in serum DNA derived from CRC patients, but
rarely in healthy subjects, indicating potential as a
biomarker for early diagnosis of CRC [20]. The
syndecan-2 (SDC2) protein functions as an integral
membrane protein and participates in cell proliferation,
cell migration, and cell-matrix interactions via its recep-
tor for extracellular matrix proteins [21, 22]. In this
study, we used a bisulfite-pyrosequencing methylation
assay on an independent group of CRC patients to con-
firm the high prevalence of aberrant SDC2 methylation
in tumor tissues of CRC patients and precancerous biop-
sies with various stages compared to those of normal tis-
sues. For the clinical validity of stool-based SDC2
methylation assay in detecting CRC, we introduced a
very sensitive and accurate method that consists of
quantitative methylation-specific PCR coupled with lin-
ear target enrichment (LTE-qMSP). The clinical validity
of the early CRC detection using LTE-qMSP for SDC2
methylation in stool DNA was assessed by comparing
observation for patients with various stages of CRC and
precancerous lesions to those of healthy individuals. The
results indicated that SDC2 methylation has high
potential as a biomarker useful in noninvasive diagnos-
tics of early-stage CRC.
Methods
Reagents
All chemical reagents used were purchased from Sigma-
Aldrich (MO, USA) unless otherwise noted. Oligonucle-
otides and fluorescent probes were synthesized by
Integrated DNA Technologies (Iowa, USA).
Cell line and clinical specimens
Human colon cancer cell HCT116, SW480, and HT-29
were obtained from Korean Cell Line Bank (Seoul, South
Korea) and maintained in RPMI 1640 medium (JBI,
Seoul, South Korea) supplemented with 10% fetal bovine
serum (JBI, Seoul, South Korea), 100 unit/mL of penicil-
lin (JBI, Seoul, South Korea), and 100 μg/mL of strepto-
mycin (JBI, Seoul, South Korea) in a humidified
incubator at 37 °C with 5% CO2.
Paraffin sections of polyp tissues (n = 49) and fresh-
frozen sections of primary colorectal tumor tissues (n =
18) were obtained from College of Medicine, Soonchun-
hyang University (Chonan, South Korea). Briefly, tissue
blocks were cut with a standard microtome (Leica
Biosystems, Nussloch, Germany) to generate successive
sections. They were mounted onto adhesive silane-
coated slides. Polyp and tumor components were identi-
fied and marked on hematoxylin and eosin stained
sections for further DNA studies by an expert surgical
pathologist. Genomic DNA (n = 5) from normal mucosa
without any history of malignancy were purchased from
BioChain Institute (CA, USA).
Stool samples from patients with histology-confirmed
CRC (n = 50), adenomatous polyps (n = 21), and healthy
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normal subjects without any history of malignancy (n =
22) were obtained from Cancer Center of Yonsei
University College of Medicine (Seoul, South Korea) and
Dongguk University Ilsan Hospital (Ilsan, South Korea).
All stool samples were collected prior to colonoscopy or
purgative bowel preparation. The collection paper
(JeongHyun MED, Seoul, South Korea) mounted to the
toilet seat was used to prevent contamination of toilet
water. Approximately 10 g of a single stool from each
individual was collected from four to five different spots
in 20 mL of preservative buffer (Genomictree, Inc.,
Daejeon, South Korea) using spatula. All stool samples
were stored at 4 °C until used. Detailed characteristics of
enrolled patients are summarized in Table 1. This study
was approved by the Institutional Review Board of
College of Medicine of Soonchunhyang University,
Dongguk University Ilsan Hospital, and Cancer Center
of Yonsei University College of Medicine. Written
informed consent was obtained from all study partici-
pants, adhering to local ethics guidelines.
DNA isolation
For fresh-frozen tissues, specimens were embedded in
Tissue-Tek O.C.T compound (Sakura Finetek, Torrance,
USA) and frozen at − 20 °C in cryostat chamber (Leica
Biosystems, Nussloch, Germany). Five to seven frozen
tissue sections (12 μm in thickness) and four to six
sections (10 μm in thickness) of formalin-fixed paraffin-
embedded (FFPE) tissues were prepared using
microtome (Leica Biosystems, Nussloch, Germany). To
remove paraffin for FFPE sections, 1.0 mL of xylene was
added to paraffin sections in 2.0 mL of microcentrifuge
tubes and incubated at room temperature for 10 min.
Tubes were centrifuged at 12,000×g for 10 min at room
temperature, and the supernatant was discarded. This
process was repeated until paraffin was fully removed.
One milliliter of ethanol was added to each tube and
vigorously shaken to wash out xylene, followed by
centrifugation at 12,000×g for 10 min. This was repeated
three times. All genomic DNA was isolated from tissues
and cell lines using QiaAmp DNA Mini kit (QIAGEN,
Hilden, Germany) according to manufacturer’s instructions.
All stool samples were washed in excess volume of
PBS at once and homogenized in EDTA-based buffer
solution (1 mL solution per 0.6 g of stool) with a shaker
device. After homogenization, 1 g equivalent of each
stool was centrifuged. The supernatants were removed
and added 1.0 to 1.4 mL of lysis buffer 1 (Genomictree,
Inc., Daejeon, South Korea) to the pellet and incubated
for 4 min at room temperature. The samples were
centrifuged and removed the supernatant, followed by
addition of lysis buffer 2 (Genomictree, Inc., Daejeon,
South Korea). The samples were incubated for 2 min at
room temperature and centrifuged. 0.75 mL of the
supernatant was aliquoted and added 25 μL of protein-
ase K (0.4 mg/mL) and incubated at 70 °C for 10 min.
The samples were subsequently extracted with tris-
saturated phenol-chloroform-isoamylalcohol (25:24:1 by
volume) (Thermo Scientific, MA, USA). Total nucleic
acids were then precipitated (1/10 volume of 3 mol/L
sodium acetate and equal volume of isopropanol,
removed from solution by centrifugation. The DNA
pellet was washed with 70% ethanol and dried. The
DNA samples were dissolved in 50 to 100 μL of TE
buffer and stored at − 20 °C. Stool DNA was also
extracted using QIAamp DNA Stool Mini Kit (QIAGEN,
Hilden, Germany) according to manufacturer’s instruc-
tion and finally eluted with 50 μL of elution buffer.
Initial homogenization steps are same and 0.2 g of stool
was used for DNA extraction. The DNA concentration
Table 1 Clinicopathological features of colorectal tissue and
stool samples used in this study
Characteristics Number of patients (%)
Tissues Stool
Healthy normal n = 5 n = 22
Sex (%)
Male 4 (80.0) 12 (54.5)
Female 1 (20.0) 10 (45.5)
Age, mean (range) 55.5 (48–65) 58.8 (36–77)
Polyp n = 49 n = 21
Sex (%)
Male 37 (75.5) 13 (61.9)
Female 12 (24.5) 8 (38.1)
Age, mean (range) 57.2 (28–89) 63.4 (51–75)
Number of polyps analyzed from each patient (range, 1–6) (%)
1 21 (42.9) 3 (14.3)
2–3 23 (46.9) 15 (71.4)
≥ 4 5 (10.2) 3 (14.3)
Histopathology
Hyperplastic 17 (34.7)
Tubular 27 (84.3) 21 (100)
Tubularvillous 5 (15.7)
CRC n = 18 n = 50
Sex (%)
Male 8 (40.0) 30 (60.0)
Female 12 (60.0) 20 (40.0)
Age, mean (range) 63.1 (39–80) 61.9 (41–84)
Stage (%)
I 2 (10.0) 12 (24.0)
II 12 (60.0) 17 (34.0)
III 2 (10.0) 10 (20.0)
IV 4 (20.0) 11 (22.0)
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was measured by Qubit dsDNA BR assay kit (Thermo
Scientific, MA, USA).
Bisulfite treatment
Genomic DNA was chemically modified with sodium
bisulfite to convert all unmethylated cytosine to uracil
while leaving methylated cytosine unmodified using EZ
DNA Methylation-Gold kit (ZYMO Research, CA, USA)
according to manufacturer’s instructions. Briefly, genomic
DNA was treated with sodium bisulfite at 65 °C for 2.5 h.
Desulfonation was performed at room temperature for
20 min. Bisulfite-converted DNA was purified using
Zymo-Spin IC column (Zymo Research, CA, USA) and
eluted with 10 μL of distilled water. The eluted DNA was
either used immediately for methylation analysis or stored
at − 20 °C until further use.
Bisulfite-pyrosequencing methylation assay of SDC2 gene
in tissues
To quantify methylation levels of SDC2, quantitative
bisulfite-pyrosequencing was performed. Specific
bisulfite PCR and pyrosequencing primers were
designed to analyze 149 bp of 5′ regulatory region
including four CpG dinucleotides sites (+456, +460,
+466, +473 bp) of SDC2 gene using PyroMark Assay
Design Software v. 2.0 (QIAGEN, Hilden, Germany).
The following primers were used: forward, 5′-
GGGAGTAGGAGTAGGAGGAGGAA-3′; reverse, 5′-
Biotin-ACCAAAACAAAA CCAAACCTCCTACCCA-
3′; sequencing primer, 5′-AGGAGGAGGAAGAGAG-
3′. Briefly, 20 ng of bisulfite-modified DNA was amp-
lified in a 25 μL reaction volume with gene-specific
primers using PyroMark PCR kit (QIAGEN, Hilden,
Germany). Samples were heated to 94°C for 10 min and
then amplified for 45 cycles at 94°C for 30 s, 56°C for 45 s,
and 72°C for 40 s. All reactions were then incubated
at 72°C for 10 min for final extension. Pyrosequenc-
ing was performed using PyroMark Gold Q96 reagent
and PyroMark ID96 instrument (QIAGEN, Hilden,
Germany) following manufacturer’s instructions.
Briefly, 25 μL of each biotinylated PCR product was
immobilized on streptavidin-coated Sepharose HP
beads (Amersham Biosciences, NJ, USA) and then
subjected to sequencing using automatically generated
nucleotide dispensation order of “sequence to analyze”
corresponding to each reaction.
Each CpG site was assigned a percentage (%) of
methylation by evaluating C/T ratio as methylation
index (MtI). The average % of methylation across four
CpG sites was obtained. Methylated non-CpG cytosines
were used as internal controls to check the fidelity of
bisulfite conversion. If MtI of each sample was greater
than 5% of detection limit of pyrosequencing [23], it was
considered as methylation-positive.
Analytic performance of meSDC2 LTE-qMSP
Analytic performance of meSDC2 LTE-qMSP was
determined for PCR replicate by testing aliquots of
DNA. To examine the limit of detection (LoD) of SDC2-
methylated DNA, HCT116 genomic DNA as fully meth-
ylated human genomic DNA was serially diluted with an
unmethylated genomic DNA. The unmethylated
genomic DNA was prepared by whole genome amplifi-
cation of human lymphocyte genomic DNA (BioChain
Institute Inc., CA, USA) using Illustra GenomiPhi V2
DNA Amplification kit (GE Healthcare, OH, USA) [24].
For comparison of meSDC2 LTE-qMSP with our previ-
ous meSDC2-qMSP assay [20], different amounts (200,
100, 50, 20, 10, and 0 pg) of fully methylated HCT116
genomic DNA were diluted into unmethylated genomic
DNA in total 20 ng of genomic DNA to create mixtures
with methylation percentages of 1.0, 0.5, 0.25, 0.1, 0.05,
and 0%. Resultant DNA samples from each concentra-
tion were pooled and divided to multiple aliquots so that
the same DNA substrate was used in PCR for compari-
son. meSDC2-qMSP and meSDC2 LTE-qMSP were
performed in 24 replicates (8 replicates in 3 independent
runs using the same real-time PCR instrument on the
same day). Primers and probes used for meSDC2 LTE-
qMSP and meSDC2-qMSP are listed in Table 2.
Methylation measurement in stool DNA by meSDC2
LTE-qMSP
For measurement of SDC2 methylation, LTE was
introduced in step 1 in order to specifically enrich meth-
ylated SDC2 target DNA from bisulfite-modified DNA.
Additionally, the region lacking CpG dinucleotides of
COL2A1 gene was used as a control [25] for estimation
of the amount of amplifiable template and adequacy of
bisulfite conversion. A total of 20 μL of reaction mixture
contained 2.0 μg of bisulfite-converted stool DNA, each
0.05 μM of SDC2 methylation-specific antisense and
COL2A1 gene-specific antisense primers attached to 5′
universal sequence, and 4 μL of 5× AptaTaq PCR master
mix (Roche Diagnostics, Basel, Swiss). Thermal cycling
conditions were as follows: 95 °C for 5 min followed by
35 cycles of 95 °C for 15 s and 60 °C for 60 s. After LTE,
the reaction mixture volume was scaled up to 40 μL,
containing 8 μL of 5× AptaTaq PCR master mix,
0.25 μM of SDC2 methylation-specific sense primer,
0.125 μM of SDC2 probe (FAM), 0.125 μM of COL2A1
sense primer, 62.5 nM of COL2A1 probe (Cy5), and
0.25 μM of universal sequence primer. Real-time PCR
was performed on a Rotor-Gene Q real-time PCR
system (QIAGEN, Hilden, Germany). Thermal cycling
conditions were as follows: 95°C for 5 min and then
40 cycles of 95 °C for 15 s and 60 °C for 60 s. Heating
and cooling rates were 20 °C per second and 15 °C per
second, respectively. For each run, bisulfite-converted
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methylated (HCT116) and unmethylated genomic DNA
were used as methylation controls. Non-template con-
trol was also included. Cycle threshold (CT) value was
calculated using Rotor Gene Q software.
The cutoff value of CT in real-time PCR assay for
SDC2 methylation was chosen based on the receiver op-
erating characteristics curve (ROC) analysis on assay re-
sults. An optimal cutoff of CT value for optimal
sensitivity and specificity discriminating CRC patients
from healthy subjects was determined at 40. Therefore,
in interpreting LTE-qMSP assay for SDC2 methylation,
if CT value was within 40 cycles, a sample was positive
and treated as negative if the CT value for SDC2 methy-
lation was undetectable. In analytic performance test for
COL2A1 with serially diluted genomic DNA (HCT116),
LoD was 10 pg (~ 3 genome copies) at 36 of CT value
(data not shown). Thus, the test result was accepted only
when the CT value of COL2A1 was ≤ 36.
Statistical analysis
All statistical analysis was performed using MedCalc ver-
sion 9.3.2.0 (MedCalc software, Ostend, Belgium). A P
value of less than 0.05 was considered statistically signifi-
cant. ROC, area under ROC (AUC), and 95% confidence
intervals (CI) were calculated. Kruskal-Wallis test was
performed to compare methylation levels and clinico-
pathological features.
Results
SDC2 methylation status in various stages of colorectal
tissues
Previously, we have reported that CpG sites of SDC2
regulatory region are most differentially methylated
between CRC and normal tissues [20]. To know how
early such aberrant SDC2 methylation might occur dur-
ing tumorigenesis of CRC, SDC2 methylation status was
analyzed using bisulfite-pyrosequencing assay in tissue
lesions with various severity, including hyperplastic
polyps (n = 17), precancerous adenomatous (n = 32), and
colorectal tumors (n = 18). In addition, normal mucosal
tissues (n = 5) were included for comparison. When
determining positive call at a cutoff value of 5.0%, a
detection limit in pyrosequencing [23], frequency of
aberrant SDC2 methylation in cancerous tissues and
precancerous lesions was significantly different from that
of normal mucosa (P < 0.01). Positive SDC2 methylation
was observed in 100% (18/18) of primary tumors, 90.6%
(29/32) of adenomas, 94.1% (16/17) of hyperplastic
polyps, and 0% (0/5) in normal tissues. The level (MtI)
of SDC2 methylation was associated with increasing
severity of lesions (Fig. 1). Overall mean MtI values (± SD)
of normal mucosa, hyperplastic polyps, adenomatous
polyps, and primary tumors were estimated at 2.0 ± 0.2,
17.6 ± 8.6, 22.4 ± 14.6, and 43.5 ± 21.0%, respectively (P <
0.01). These results indicated that SDC2 methylation level
was increased in accordance with severity of lesions.
Development of meSDC2 LTE-qMSP assay
Analyzing methylation status of the region of interest of
target DNA, SDC2 here, in stool DNA is a formidable
challenge because target DNA exists at considerably low
copy number with extremely high level of background
noise from unrelated genomic DNA (derived from het-
erogeneous origins).
To address this issue, we developed and launched this
study to establish a new method demonstrating highly
Table 2 Comparison of meSDC2 LTE-qMSP with meSDC2-qMSP
Description meSDC2 LTE-qMSP meSDC2-qMSP
SDC2
Primer sequencesa
5′-GTAGAAATTAATAAGTGAGAGGGC-3′
5′-AAAGATTCGGCGACCACCGAACGACTCAAACTCGAAAACTCG-3′
F: 5′-TAGAAATTAATAAGTGAGAGGGCGT-3′
R: 5′-GACTCAAACTCGAAAACTCGAA-3′
SDC2 probea 5′-FAM-TTCGGGGCGTAGTTGCGGGCGG-3′ 5′-FAM-AGTAGGCGTAGGAGGAGGAAGCGA-3′
SDC2 amplicon size 124 bp 121 bp
Real time PCR
reagents
AptaTaq DNA Master, 5X Rotor-Gene Probe PCR Kit
Thermal cycling
condition
LTE: 95 °C 5 min; 95 °C 15 s, 60 °C 1 min, 35 cycles; heating and cooling
rates were 15 and 20 °C/s.
qMSP: 95 °C 5 min; 95 °C 15 s, 60 °C 1 min, 40 cycles; heating and
cooling rates were 15 and 20 °C/s.
qMSP: 95 °C 5 min; 95 °C 10 s, 62 °C 15 s, 72 °C 20 s;
40 cycles; heating and cooling rates were
15 and 20 °C/s.
Control gene COL2A1 ACTB
Primer sequencesa 5′-GTAATGTTAGGAGTATTTTGTGGITA-3′
5′-AAAGATTCGGCGACCACCGACTAICCCAAA AAAACCCAATCCTA-3′
F: 5′-TGGTGATGGAGGAGGTTTAGTAAGT-3′
R: 5′-AACCAATAAAACCTACTCCTCCCTT AA-3′
COL2A1 probea 5′-Cy5-AGAAGAAGGGAGGGGTGTTAGGAGAGG-3′ 5′-TET-ACCACCACCCAACACACAATAACAAACA CA-3′
COL2A1 amplicon
size
86 bp 133 bp
Bold identical nucleotide sequences with meSDC2-qMSP assay, italics universal sequence, I inosine nucleotide, F and R indicate forward and reverse
primers, respectively
aCpG dinucleotide sites are underlined
Oh et al. Clinical Epigenetics  (2017) 9:126 Page 5 of 11
sensitive and specific quantitative detection of SDC2
methylation in stool DNA, named as meSDC2 LTE-
qMSP covering CpG targets (+ 377 to + 500 bp),
outlined in Fig. 2a.
This method implements two rounds of consecutive
PCR consisting of (1) unidirectional linear amplification
for target DNA and control by PCR and (2) quantitative
real-time PCR for methylation analysis for target region
of SDC2.
For the first round PCR, two primers, antisense-
methylated SDC2 specific and control COL2A1 specific
primers with the same universal tag sequence at 5′ end
for second round PCR were simultaneously used for
linear target enrichment of SDC2 methylation and
control COL2A1. In the second round of PCR, conven-
tional qMSP by real-time PCR procedure for SDC2
methylation was conducted using sense SDC2 specific
primer and universal sequence-matched primer with
methylation-specific dual labeled probe. This method
was selected to optimally enhance sensitivity and dimin-
ish non-specific amplification during intensive DNA
amplification and compensate for frequent artifacts seen
in two round PCR. To evaluate analytic performance of
new method, meSDC2 LTE-qMSP assays were con-
ducted repeatedly (24 times) using bisulfite-treated mix-
ture of genomic DNA (total 20 ng, ~ 6200 genome
copies) as an initial template (different ratio of genomic
DNA mixture), resulting in methylation percentages of
1.0, 0.5, 0.25, 0.1, 0.05, and 0%, respectively (between
fully methylated and unmethylated genomic DNA).
Regarding specificity testing, various amounts (105 to
109 copies) of plasmids (representing fully unmethylated
SDC2 DNA sequence) were implemented as a template
for the assay. The meSDC2 LTE-qMSP detected SDC2
methylation levels as low as 0.05% (~ 3 genome copies)
and revealed no cross reactivity, even with excess 109
copies of plasmids (data not shown). If LoD is defined as
“a condition showing positive in more than 95% of 24
repeated assays” [26], LoD of meSDC2-qMSP was 0.1%
methylation corresponding to 20 pg (~ 6 genome copies
in ~ 6200 copies of total template) in which detection
rate was 100% (Fig. 2b).
To compare the performance of LTE-qMSP with
conventional qMSP, qMSP assays (meSDC2-qMSP) for
SDC2 methylation covering CpG targets (+ 377 to +
498 bp) [20] was evaluated in the same way with differ-
ent ratio of genomic DNA mixtures, resulting in that
LoD of meSDC2-qMSP was 0.5% methylation equivalent
to 100 pg (~ 30 genome copies). This data indicated that
LTE-qMSP assay achieved 5-fold improvement in LoD
compared with qMSP for SDC2 methylation. As well,
CT value for methylated SDC2 was detected several
cycles earlier by the meSDC2 LTE-qMSP method, when
compared to that of the meSDC2-qMSP assay for all
dilutions of methylated SDC2 (Table 3). Linear
regression analysis of meSDC2 LTE-qMSP for SDC2
methylation demonstrated reproducible linearity, with a
correlation coefficient of R2 = 0.992 (data not shown).
Feasibility test of using SDC2 methylation in stool DNA-
based assay for detection of CRC and precancerous
lesions
To determine whether measurement of SDC2 methy-
lation in stool DNA was capable of detecting CRC
and adenoma, meSDC2 LTE-qMSP was performed
using stool DNA from 50 CRC patients at various
stages and 21 patients with small size (< 1.0 cm) of
adenoma. In addition, stool DNA from 22 healthy
normal subjects were included. meSDC2 LTE-qMSP
showed significant higher frequency of aberrant SDC2
methylation in stool DNA from both CRC (P < 0.01)
and adenoma (P < 0.05) patients compared to that in
healthy normal subjects (Fig. 3a). Meanwhile, 20 out
of 22 healthy subjects showed an absence of methyla-
tion, indicating that SDC2 methylation in stool
samples had high specificity. To evaluate clinical
performance of SDC2 methylation in detection of
CRC, ROC curve was constructed by optimizing
sensitivity and specificity using assay results. ROC
analysis determined optimal cutoff value of CT at 40
with AUC of 0.933 (95% CI 0.848–0.978) (Fig. 3b).
Overall sensitivity of testing for detection of CRC was
Fig. 1 Assessment of methylation levels of the SDC2 gene in
colorectal tissues by bisulfite-pyrosequencing. Methylation level of
the SDC2 gene was evaluated in normal mucosa (N), hyperplastic
(HP) and adenomatous polyps (Ade), and CRC tissues. The MtIs of
each sample are represented by box and whisker plots. The
difference in MtI of SDC2 is statistically significant at *P < 0.01
calculated by Kruskal-Wallis test in adenomatous polyps vs. normal
controls, hyperplastic polyps vs. normal controls, CRC vs. normal
controls, and CRC vs. adenomatous polyps
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estimated at 90.0% (45/50, 95% CI 78.2–96.6%) with
specificity of 90.9% (2/22, 95% CI 70.8–98.6%). Sensi-
tivities for individual stages I, II, III, and IV were
83.3% (10/12), 88.2% (15/17), 90.0% (9/10), and 100%
(11/11), respectively. SDC2 methylation was also
detected in 7 (33.3%) of 21 adenomas < 1.0 cm. Thus,
the sensitivity tended to be gradually increased in
accordance with the severity of neoplasms.
Discussion
The results of this study indicate that quantifying the
methylation level of SDC2 in exfoliated epithelial cell-
derived DNA isolated from human stool would be a new
useful noninvasive screening tool for early-stage CRC.
Screening tests have effectively reduced disease related
CRC mortality, and there are currently several options
available to screen the CRC. Although immunochemical
a
b
Fig. 2 Schematic diagram and analytic performance of meSDC2 LTE-qMSP. a Outline of meSDC2 LTE-qMSP. LTE was first performed using two
primers: SDC2 and COL2A1 antisense primers attached to a universal primer to enrich methylated SDC2 DNA, and consecutive duplex real-time
PCR was carried out using methylation-specific SDC2 sense primer, COL2A1-specific sense primer, universal primer, and probes. b The LoD of
meSDC2 LTE-qMSP was compared with that of meSDC2-qMSP. Different amounts of HCT116 genomic DNA were diluted in unmethylated
genomic DNA in total 20 ng of genomic DNA
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FOBT is the most widely used method to detect early-
stage CRC, it is limited by its low sensitivity of 65.8%
[6]. A colonoscopy offers the most complete and sensi-
tive test that is currently available. However, a colonos-
copy is an invasive method to screen CRC that requires
extensive bowel preparation, and it could lead to serious
complications, so many patients find it undesirable.
Thus, stool DNA-based molecular marker tests have
been recently proposed as a new alternative to screen
early-stage CRC [27].
Aberrant DNA methylation of some genes has been
known to occur early during tumorigenesis. Therefore,
specific methylation sites have been considered as poten-
tial biomarkers for the early diagnosis of cancer [28].
Previously, we identified that the CpG island of SDC2
that is normally unmethylated was one of most predom-
inantly methylated DNA sites in tumors of CRC
patients, regardless of stage. The 5′ regulatory region of
SDC2 plays a role as diagnostic biomarker for early
detection of CRC because this region was frequently
hypermethylated in CRC, while unmethylated in healthy
normal controls. We then demonstrated that aberrant
methylation status of SDC2 can be readily detected in
DNA derived from the bodily fluids, such as serum and
stool, of patients with CRC [20, 29], indicating its poten-
tial as a noninvasive molecular diagnostic biomarker for
the early detection of CRC. A frequent SDC2 hyperme-
thylation was in tissues of gastric cancer, and aberrant
methylation of SDC2 was correlated with diffuse-type
and mixed-type gastric cancers [30]. SDC2 hypermethy-
lation was in HPV-positive primary tumor of head and
neck squamous cell cancer and glioma multiforme [31,
32]; however, details of clinical performance of SDC2
methylation test were not addressed in these studies.
In the present study, we attempted to determine
whether stool DNA-based test using SDC2 methylation
as a biomarker was a viable option to detect CRC. We
first confirmed that the abnormal methylation of SDC2
occurs in almost all CRC tissues regardless of stage and
is observed also in biopsies of various precancerous
lesions while not detected in normal mucosal tissues.
The methylation level of SDC2 in tissue samples tend to
increased according to the severity of lesions.
Developing sensitive stool DNA-based methylated
DNA tests for early detection of CRC is challenging for
a number of reasons. Normally, stool contains a mixture
Table 3 Comparison of analytic performance between a meSDC2 LTE-qMSP and meSDC2-qMSP
DNA
Concentration (pg)
meSDC2 LTE-qMSP detected meSDC2 LTE-qMSP Avg CT meSDC2-qMSP detected meSDC2-qMSP Avg CT
200 24 out of 24 25.0 24 out of 24 32.8
100 24 out of 24 26.0 23 out of 24 33.2
50 24 out of 24 27.3 19 out of 24 34.9
20 24 out of 24 29.6 9 out of 24 35.9
10 8 out of 24 33.9 0 out of 24 N.D
Negative control 0 out of 24 N.D 0 out of 24 N.D
N.D not detected
a b
Fig. 3 Methylation status of SDC2 in stool DNA by meSDC2 LTE-qMSP test. a meSDC2 LTE-qMSP test was performed in stool DNA from CRC
patients in varying stages, adenoma patients (Ade), and healthy normal subjects (N). Distribution of the relative level of SDC2 methylation was
expressed in CT values as 40-CT for each sample. A higher 40-CT represents a higher methylation level of SDC2. It is represented as 0, if the SDC2
CT was not detected. Methylation status of the SDC2 gene is plotted as box and whisker plots. The difference in methylation level of SDC2 was
statistically significant at **P < 0.01 and *P < 0.05 calculated by Kruskal-Wallis test in CRC patients vs. healthy normal subjects and adenoma
patients vs. healthy normal subjects, respectively. b ROC curve was plotted for CRC patients vs. healthy normal subjects. The cutoff value for
methylation-positive and AUC are indicated in the plot
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of cells such as exfoliated epithelial cells from colon
mucosa and others and in case of CRC patients a small
fraction of the neoplastic cells shed from tumor lesions
[33–35]. Furthermore, DNA derived from bacteria and
diets tend to increase heterogeneity of stool-derived
DNA [36–38]. To complicate matters, the presence of
various interference/contaminating factors in the stool
might inhibit PCR reactivity. Keeping in mind these vari-
ous issues, we here introduced a LTE-qMSP, a highly
sensitive and specific methylation detection method that
employs two-step PCR procedures on bisulfite-treated
purified stool DNA and combines linear target enrich-
ment for methylated SDC2 and target amplification via
real-time PCR for SDC2 methylation. Pyrosequencing
measures methylation status of individual and multiple
CpG sites. LoD of pyrosequencing is as low as 5%
fraction of methylated DNA in the background of
unmethylated DNA [23]. Our new LTE-qMSP measures
absolute methylation level (CT) of multiple CpG sites
covered by methylation-specific primers and probe.
LTE-qMSP has a LoD of 0.1% fraction of methylated
DNA in the background of unmethylated DNA. In our
preliminary study, pyrosequencing revealed low sensitiv-
ity for detection of SDC2 methylation in stool DNA
(data not shown). Thus, LTE-qMSP had an advantage of
higher detection sensitivity for SDC2 methylation com-
pared with pyrosequencing.
In this study, we applied LTE-qMSP assay to measure
SDC2 methylation status in stool DNA from 50 CRCs,
21 adenomas, and 22 healthy individuals. A single reac-
tion of meSDC2 LTE-qMSP revealed overall sensitivity
of 90.0% for detection of CRC with slightly lower sensi-
tivity for early stage than later stage CRCs with 83.3%
sensitivity for stage I and a specificity of 90.9% for
healthy subjects. In terms of specificity matter, 9.1% of
healthy individuals revealing SDC2 methylation-positive
are counted as false-positive. However, considering that
not all healthy subjects were verified with colonoscopy
as adenomatous polyp-free and more than 30% of
asymptomatic adults older than 50 had polyps [39],
possibility that those healthy subjects revealing SDC2
methylation-positive have polyp(s) cannot be excluded.
Specificity should be further evaluated in a number of
colonoscopy-determined normal controls in future
studies. In addition, we examined frequency of aberrant
SDC2 methylation in stool DNA from patients with a
small size of adenomas (< 1.0 cm) and estimated 33.3%
of sensitivity. Notably, as compared to a single test when
another reaction of meSDC2 LTE-qMSP was applied on
the remaining stool DNA and the sample classified
positive based on at least one positive for methylation out
of the two reactions, the sensitivity increased from 33.3 to
42.9%, as compared to a single test (data not shown). This
suggests that multiple tests of LTE-qMSP for SDC2
methylation in stool DNA probably increase clinical
sensitivity in detecting early stage of CRC as well as
advanced polyps. Since the ultimate aim of screening is to
prevent of CRC, screening test should be effective to
detect those precancerous lesions at the risk of CRC
progression [17]. When small size (< 1.0 cm) of adenomas
was detected, the patients will be generally subjected to
observation. However, large adenomas > 1.0 cm or
multiple adenomas are more likely to progress to CRC,
and they are currently subjected to be removed during
colonoscopy. Therefore, it will be worthy to investigate
how well SDC2 methylation test can detect advanced or
multiple precancerous lesions in future studies.
Several groups have reported studies examining DNA
methylation biomarker performance in stool DNA for
early detection of CRC or precancerous lesions [9, 16,
40, 41]. For example, SFRP2 has shown a sensitivity of
77–90% with specificity of 77% to detect CRC in stool
samples, indicating an excellent sensitivity but unsatis-
factory specificity [40]. HIC1 and vimentin genes have
sensitivities of 42 and 46%, respectively, with specificities
of 100 and 90%, respectively, to detect CRC in stool
DNA [16, 41]. Huang et al. [4] analyzed the methylation
of multiple genes (SFRP2, HPP1, and MGMT) in stool
DNA from a large population. The sensitivity and speci-
ficity to detect CRC in the three combined genes was
96.2 and 95.8%, respectively.
On the other hand, Ahlquist et al. [17] reported a next
generation stool DNA test using multiple markers, includ-
ing four methylated genes (vimentin, NDRG4, BMP3,
TFPI2) and KRAS mutations. This test was able to detect
CRC and precancerous adenoma with sensitivities of 85
and 54%, respectively, at a specificity of 90% [17]. In
addition, a recent study by Imperiale et al. [19] reported a
stool-based multi-target test composed of seven sites of
KRAS mutation, two methylation markers (NDRG4 and
BMP3), and FIT. Multi-target stool testing showed a
sensitivity of 92.0% to detect CRC and 42.4% for advanced
precancerous lesions at a specificity of 87.0%.
Mitchell et al. [42] recently performed genome-wide
methylation analysis with DNA microarray in CRC
tumors compared to matched-normal tissues and
observed that SDC2 gene was frequently methylated
tumors. Subsequently they confirmed that SDC2
methylation was evident in 80% or more of the tested
cancer tissues by qMSP. Very recently while we were
preparing this manuscript for publication, Niu et al.
[18] published a paper showing that methylation tests
of SDC2 in fecal DNA detects CRC and advanced
adenoma (≥ 1.0 cm) with sensitivities of 81.1 and
58.2%, respectively, at a specificity of 93.3%. Both data
are comparable to ours and indicating that SDC2
methylation event has a high potential as an early
diagnostic biomarker for CRC.
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In a tissue level, SDC2 methylation events have been
observed in all tumor tissues of most CRC patients but
have never been observed in normal colon tissues by
pyrosequencing-based methylation assay having a detec-
tion limitation of 5% [23]. In the stool DNA test, ROC
analysis on assay results determined an optimal cutoff
for SDC2 methylation for detecting CRC at CT value of
40. Thus, a sample was treated as positive if CT value for
SDC2 methylation was within 40 and considered as
negative if the CT value for SDC2 was not detectable.
Healthy individuals showed a very rare frequency (9.1%)
of methylation-positive. Therefore, SDC2 methylation
can be easily added to the other biomarkers reported
above, thereby improves clinical performance for the
early diagnosis of CRC, without losing specificity.
This study has a limitation in the small size of the
patient and normal groups. Therefore, future large-scale
of investigation for clinical validation of SDC2 methyla-
tion and intensive evaluation of the ethnic or regional
difference will be warranted.
Conclusions
We previously identified a novel potential methylation
marker SDC2 for the early detection of CRC. In this
study, to validate SDC2 methylation is able to detect
patients with CRC and precancerous lesion using stool
DNA, we developed a sensitive stool-based meSDC2
LTE-qMSP. Our results demonstrate that abnormal
SDC2 methylation is a frequent event in precancerous
adenomas and CRC but is negative in normal mucosa.
Our results suggest that SDC2 methylation is a new
potential diagnostic biomarker for noninvasive screening
of CRC.
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